Orchestra BioMed Holdings, Inc.

NasdaqGM:OBIO Stock Report

Market Cap: US$181.3m

Orchestra BioMed Holdings Management

Management criteria checks 2/4

Orchestra BioMed Holdings' CEO is David Hochman, appointed in May 2018, has a tenure of 6.58 years. total yearly compensation is $6.90M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 1.09% of the company’s shares, worth $1.97M. The average tenure of the management team and the board of directors is 2.3 years and 6.1 years respectively.

Key information

David Hochman

Chief executive officer

US$6.9m

Total compensation

CEO salary percentage8.6%
CEO tenure6.6yrs
CEO ownership1.1%
Management average tenure2.3yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

Here's Why We're Watching Orchestra BioMed Holdings' (NASDAQ:OBIO) Cash Burn Situation

Dec 18
Here's Why We're Watching Orchestra BioMed Holdings' (NASDAQ:OBIO) Cash Burn Situation

Orchestra BioMed Holdings (NASDAQ:OBIO) Has Debt But No Earnings; Should You Worry?

Mar 01
Orchestra BioMed Holdings (NASDAQ:OBIO) Has Debt But No Earnings; Should You Worry?

CEO Compensation Analysis

How has David Hochman's remuneration changed compared to Orchestra BioMed Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$56m

Mar 31 2024n/an/a

-US$52m

Dec 31 2023US$7mUS$595k

-US$49m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$43m

Mar 31 2023n/an/a

-US$39m

Dec 31 2022US$3mUS$395k

-US$34m

Sep 30 2022n/an/a

-US$32m

Jun 30 2022n/an/a

-US$27m

Mar 31 2022n/an/a

-US$25m

Dec 31 2021US$710kUS$395k

-US$23m

Compensation vs Market: David's total compensation ($USD6.90M) is above average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Hochman (49 yo)

6.6yrs

Tenure

US$6,899,668

Compensation

Mr. David P. Hochman is Founder & Director at Orchestra BioMed Holdings Inc. (formerly known as Health Sciences Acquisitions Corporation 2) since May 2018 and serves as its Chief Executive Offer and Chairm...

Leadership Team

NamePositionTenureCompensationOwnership
David Hochman
Founder6.6yrsUS$6.90m1.09%
$ 2.0m
Darren Sherman
Founder6.6yrsUS$6.45m0.53%
$ 959.4k
Andrew Taylor
Chief Financial Officer1.5yrsUS$2.57m0.16%
$ 292.1k
William Little
Executive Vice President of Corporate Development & Strategy1.5yrsno data0.81%
$ 1.5m
Yuval Mika
GM & CTO of Bioelectronic Therapies6.6yrsno data0.13%
$ 236.5k
George Papandreou
GM & Senior VP of Focal Therapies3.4yrsno data0.053%
$ 95.4k
Hans-Peter Stoll
Chief Clinical Officer2.7yrsno datano data
Avraham Fischer
Senior Vice President of Medical Affairs & Innovation1.9yrsno datano data
Bob Laughner
Senior Vice President of Regulatory & Quality1.1yrsno datano data
Juan Lorenzo
Senior Vice President of Product Development1.1yrsno datano data
Joshua Aiello
Corporate Controllerno datano datano data

2.3yrs

Average Tenure

53yo

Average Age

Experienced Management: OBIO's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
David Hochman
Founder6.6yrsUS$6.90m1.09%
$ 2.0m
Darren Sherman
Founder6.6yrsUS$6.45m0.53%
$ 959.4k
Eric Rose
Independent Director6yrsUS$138.07k0.0057%
$ 10.4k
Paul Teirstein
Member of Medical Advisors Boardno datano datano data
Vivek Reddy
Member of Medical Advisors Boardno datano datano data
Eric Fain
Independent Lead Director6.1yrsUS$243.42k0.094%
$ 170.9k
Robert Schwartz
Member of Medical Advisors Boardno datano datano data
Jason Aryeh
Independent Director6.1yrsUS$145.21k0.17%
$ 300.4k
Stefan Verheye
Member of Medical Advisors Boardno datano datano data
Roger de la Torre
Member of Medical Advisors Boardno datano datano data
Pieter Stella
Member of Medical Advisors Boardno datano datano data
Pamela Connealy
Independent Director4.8yrsUS$205.42k0.011%
$ 20.3k

6.1yrs

Average Tenure

59yo

Average Age

Experienced Board: OBIO's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 00:10
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Orchestra BioMed Holdings, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle BauserB. Riley Securities, Inc.
Keay NakaeChardan Capital Markets, LLC
Yi ChenH.C. Wainwright & Co.